- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04048824
Optimizing Exposure Therapy for Anxiety Disorders (OptEx)
Inhibitory Learning vs. Habituation: Models of Exposure Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A substantial number of individuals fail to achieve clinically significant symptom relief from exposure-based therapies or experience a return of fear following exposure therapy completion. The prevailing model of exposure therapy for phobias and anxiety disorders purports that fear reduction throughout exposure therapy (i.e., habituation) is reflective of learning and critical to overall therapeutic outcome. However, the amount by which fear - indexed by both self-report, behavioral, and biological correlates of fear expression - reduces by the end of an exposure trial or series of exposure trials is not a reliable predictor of the fear level expressed at follow-up assessment.
Developments in the theory and science of fear extinction, and learning and memory, indicate that 'performance during training' is not commensurate with learning at the process level. Inconsistent findings regarding fear reduction are paralleled by findings based in associative learning laboratory paradigms with animals and human samples, specifically that outward expression of fear on the one hand, and conditional associations indicative of underlying learning on the other hand, may not always change in concordance. Rather, 'inhibitory learning' is recognized as being central to extinction, rather than fear during extinction training.
The current proposal will compare the habituation-based model of exposure therapy to the competing inhibitory model of exposure that emphasizes learning theory principles.
The current study plans to recruit participants for a treatment trial consisting of two psychotherapies: (a) habituation-based exposure therapy and (b) inhibitory learning-based exposure therapy. The primary goal of this study is to determine if one theoretical approach to exposure outperforms the other in reducing symptoms.
This study is conducted with individuals meeting diagnostic criteria for social anxiety disorder or panic disorder. Participants will be randomized to either treatment condition and receive 9 sessions of individual psychotherapy focused on either of these disorders. If individual meets diagnostic criteria for both disorders, treatment will be focused on the primary presenting disorder. Participants will complete four assessments over the course of the study, at pre-treatment, mid-treatment, post-treatment, and three-month follow-up. Pre-treatment, mid-treatment, and post-treatment assessments occur over two days, while three-month follow-up requires only a single day and is conducted remotely.
These assessments will include semi-structured interviews, self-report questionnaires, and laboratory paradigms designed to examine fear learning processes.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Julian Ruiz, BA
- Phone Number: (562) 459-4938
- Email: jruiz@psych.ucla.edu
Study Contact Backup
- Name: Brooke Cullen, BA
- Email: brookecullen@psych.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- University of California, Los Angeles
-
Contact:
- Amy Sewart, MA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Seeking treatment for social anxiety or panic disorder and demonstration of elevated scores using standardized self-report measures and diagnostic interview
- Age 18 to 65
- Either stabilized on psychotropic medications or medication-free
- English-speaking
- Access to telehealth resources (for Zoom treatment sessions after March 2020 due to COVID-19)
Exclusion criteria include:
- Patient report of serious medical conditions - such as respiratory (e.g., chronic obstructive pulmonary disease), cardiovascular, pulmonary, neurological, muscular-skeletal diseases - or pregnancy
- Active suicidal ideation or self-harm in the past year; history of suicide attempts in the last 10 years
- History of bipolar disorder, psychosis, mental retardation or organic brain damage
- Substance abuse/dependence within last 6 months
- Concurrent therapy focused on anxiety. Participants are allowed to be in other forms of therapy, provided the therapy does not focus on anxiety (e.g., supportive counseling) and they have been stabilized on this alternative therapy for at least 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inhibitory Learning-Based Exposure
Participants will receive exposure therapy aimed at increasing inhibitory learning.
|
9 weekly treatment sessions conducted individually with a therapist.
Exposure is focused on maximizing the mismatch between participant's feared outcome and what actually occurred (i.e., expectancy violation).
This condition includes techniques that incorporate associative learning principles such as exposure to multiple feared stimuli (i.e., deepened extinction), exposure variability in contexts and stimuli, occasional reinforcement, and mental reinstatement of inhibitory learning.
|
Active Comparator: Habituation-Based Exposure
Participants will receive exposure therapy aimed at reducing fear responding.
|
9 weekly treatment sessions conducted individually with a therapist.
Exposure is focused on fear reduction from initial fear ratings.
This condition includes theoretically-consistent techniques such as staying in the situation until fear declines, repetition of exposures until fear has declined, and a gradual approach to feared stimuli using an exposure hierarchy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in clinician-rated severity of social anxiety or panic disorder
Time Frame: Pre-treatment to post-treatment (10 weeks), to follow-up (24 weeks)
|
Clinician severity rating (0-8) of social anxiety or panic disorder using the Structured Clinical Interview for DSM-5 (SCID-5).
|
Pre-treatment to post-treatment (10 weeks), to follow-up (24 weeks)
|
Change in self-reported symptom severity of social anxiety or panic disorder
Time Frame: Pre-treatment to post-treatment (10 weeks), to follow-up (24 weeks)
|
Self-reported symptom severity of social anxiety disorder using the Liebowitz Social Anxiety Scale (LSAS) or panic disorder using the Panic Disorder Severity Scale-Self Report (PDSS-SR).
|
Pre-treatment to post-treatment (10 weeks), to follow-up (24 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in fear extinction generalization as measured by expectancy of unconditional stimuli during conditional stimuli presentation.
Time Frame: Pre-treatment to post-treatment (9 weeks)
|
Change in responsiveness to fear generalized from various, perceptually similar stimuli collected during a laboratory fear paradigm.
|
Pre-treatment to post-treatment (9 weeks)
|
Change in fear extinction generalization as measured by skin conductance.
Time Frame: Pre-treatment to post-treatment (9 weeks)
|
Change in skin conductance to fear generalized from various, perceptually similar stimuli collected during a laboratory fear paradigm.
(Discontinued March 2020 due to COVID-19)
|
Pre-treatment to post-treatment (9 weeks)
|
Change in fear extinction generalization as measured by heart rate.
Time Frame: Pre-treatment to post-treatment (10 weeks)
|
Change in heart rate to fear generalized from various, perceptually similar stimuli collected during a laboratory fear paradigm.
(Discontinued March 2020 due to COVID-19)
|
Pre-treatment to post-treatment (10 weeks)
|
Implicit Fear Association Test
Time Frame: Pre-treatment to post-treatment (10 weeks)
|
Change in implicit associations for fear-relevant word stimuli
|
Pre-treatment to post-treatment (10 weeks)
|
Behavioral Avoidance Test (BAT)
Time Frame: Pre-treatment to post-treatment (10 weeks)
|
Change in duration and subjective fear of public speaking in situ
|
Pre-treatment to post-treatment (10 weeks)
|
Probability and Cost Questionnaire
Time Frame: Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
|
Change in perceived likelihood and perceived consequence of fear-relevant outcomes
|
Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
|
Anxiety Sensitivity Index (ASI-3)
Time Frame: Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
|
Change in appraisal of harmfulness of symptoms
|
Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
|
Positive and Negative Affect Schedule (PANAS 20 item)
Time Frame: Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
|
Change in affect
|
Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
|
Panic Disorder Severity Scale-Self Report (PDSS-SR)
Time Frame: Weekly throughout the duration of treatment (10 weeks) and once at follow-up (24 weeks)
|
Change in panic disorder symptoms
|
Weekly throughout the duration of treatment (10 weeks) and once at follow-up (24 weeks)
|
Sheehan Disability Scale (SDS)
Time Frame: Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
|
Change in functioning related to mental health
|
Pre-treatment to post-treatment (10 weeks) and follow-up (24 weeks)
|
Mini-SPIN
Time Frame: Weekly throughout the duration of treatment (10 weeks) and once at follow-up (24 weeks)
|
Change in social anxiety symptoms.
Scores on the Mini-SPIN range from 0 to 12 with higher scores indicating higher social anxiety severity.
|
Weekly throughout the duration of treatment (10 weeks) and once at follow-up (24 weeks)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Michelle G Craske, PhD, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Optimizing Exposure
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Social Anxiety Disorder
-
Aya Technologies LimitedCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)United Kingdom
-
Tel Aviv UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)Israel
-
Aya Technologies LimitedCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)United Kingdom
-
University of BernUniversity of LuebeckActive, not recruitingSocial Anxiety Disorder (Social Phobia)Switzerland
-
Daniel LiebermanTerminatedAnxiety | Anxiety Disorder SocialUnited States
-
Weill Medical College of Cornell UniversityBrain & Behavior Research FoundationTerminatedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States
-
Tufts UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States
-
Sumitomo Pharma America, Inc.BehaVR LLCCompletedSocial Anxiety Disorder (SAD)United States
-
Emory UniversityBristol-Myers SquibbCompleted
-
Florida International UniversityYale UniversityRecruitingSocial Anxiety Disorder of ChildhoodUnited States
Clinical Trials on Inhibitory Learning-Based Exposure
-
University of Colorado, DenverCompletedAnxiety DisordersUnited States
-
Philipps University Marburg Medical CenterCompleted
-
Na LiuNot yet recruiting
-
Ottawa Hospital Research InstituteCompletedCardiac Arrest | Basic Life SupportCanada
-
University of Nevada, RenoNot yet recruitingHealthy AgingUnited States
-
Drexel UniversityDrexel Coulter Translational Research Partnership ProgramCompletedBinge Eating | Inhibition (Psychology)United States
-
Maharishi Markendeswar University (Deemed to be...Completed
-
Chang Gung Memorial HospitalCompletedCognitive Function 1, Social | Heart Rate Fast | Otolaryngologic Disorder | Competence | Learning, SpatialTaiwan
-
MGH Institute of Health ProfessionsNational Institute on Deafness and Other Communication Disorders (NIDCD)Completed
-
HealthPartners InstituteAgency for Healthcare Research and Quality (AHRQ)Completed